文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌中膀胱镜检查所见对肿瘤学结局的影响:一项Meta分析

Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis.
PubMed 文献 · BJU Int · 2023-01-13

该Meta分析纳入73项研究共28139例非肌层浸润性膀胱癌患者,评估膀胱镜下肿瘤多发、大小及大体外观与肿瘤学结局的关联。结果显示肿瘤多发、直径≥3 cm、无蒂及实性外观均与更差的复发无生存、进展无生存相关,在T1期患者中还与更差的癌症特异性生存相关。

要点

  • 肿瘤多发与更差的RFS(HR 1.61)和PFS(HR 1.44)相关。
  • 肿瘤≥3 cm与更差的RFS(HR 1.97)和PFS(HR 1.81)相关。
  • 无蒂和实性肿瘤分别与更差的RFS和PFS相关,实性肿瘤在T1期还预测更差CSS。

核心结论

  • 膀胱镜下肿瘤多发、大小及大体外观可强烈预测NMIBC患者的肿瘤学结局。
  • 膀胱镜视觉特征有助于决定肿瘤切除的及时性和范围以及后续膀胱内治疗等管理决策。

研究设计与样本

  • Meta分析,检索多个数据库(2022年5月),纳入73项研究共28139例非肌层浸润性膀胱癌患者。

主要发现

  • 肿瘤多发与更差的RFS(合并HR 1.61,95%CI 1.48-1.74)和PFS(合并HR 1.44,95%CI 1.18-1.76)相关,见于包括Ta和T1期的NMIBC患者。
  • 肿瘤大小≥3 cm与更差的RFS(合并HR 1.97,95%CI 1.69-2.30)和PFS(合并HR 1.81,95%CI 1.52-2.15)相关,见于NMIBC患者。
  • 在T1期膀胱癌患者中,肿瘤多发和大小≥3 cm也与更差的RFS、PFS和CSS相关。
  • 在接受卡介苗(BCG)治疗的患者中,肿瘤多发与更差的RFS无关,肿瘤大小≥3 cm与更差的PFS无关。
  • 与有蒂肿瘤相比,无蒂肿瘤与更差的RFS(合并HR 2.14,95%CI 1.52-3.01)和PFS(合并HR 2.17,95%CI 1.42-3.32)相关;与乳头状肿瘤相比,实性肿瘤与NMIBC患者更差的RFS(合并HR 1.84,95%CI 1.25-2.72)和PFS(合并HR 3.06,95%CI 2.31-4.07)相关,并与T1期膀胱癌患者更差的CSS相关(合并HR 2.32,95%CI 1.63-3.30)。

关键数值与推荐

  • 肿瘤多发:NMIBC患者RFS合并HR 1.61(95%CI 1.48-1.74),PFS合并HR 1.44(95%CI 1.18-1.76)。
  • 肿瘤大小≥3 cm:NMIBC患者RFS合并HR 1.97(95%CI 1.69-2.30),PFS合并HR 1.81(95%CI 1.52-2.15)。
  • 无蒂肿瘤对比有蒂肿瘤:RFS合并HR 2.14(95%CI 1.52-3.01),PFS合并HR 2.17(95%CI 1.42-3.32)。
  • 实性肿瘤对比乳头状肿瘤:NMIBC患者RFS合并HR 1.84(95%CI 1.25-2.72),PFS合并HR 3.06(95%CI 2.31-4.07)。
  • 实性肿瘤对比乳头状肿瘤:T1期膀胱癌患者CSS合并HR 2.32(95%CI 1.63-3.30)。

临床怎么用

  • 原文结论认为膀胱镜视觉特征有助于决定肿瘤切除的及时性和范围以及后续膀胱内治疗等管理决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the association between cystoscopic findings and oncological outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) given that the oncological impact of quantity and quality assessment of tumours with cystoscopy has not been well verified. METHODS: Multiple databases were queried in May 2022 for studies investigating the association of oncological outcomes, such as recurrence-free (RFS), progression-free (PFS), and cancer-specific survival (CSS), with cystoscopic findings, including multiplicity, size, and gross appearance of tumours in patients with NMIBC. RESULTS: Overall, 73 studies comprising 28 139 patients were eligible for the meta-analysis. Tumour multiplicity was associated with worse RFS (pooled hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.48-1.74) and PFS (pooled HR 1.44, 95% CI 1.18-1.76) in NMIBC patients (including both Ta and T1). Tumour size (≥3 cm) was associated with worse RFS (pooled HR 1.97, 95% CI 1.69-2.30) and PFS (pooled HR 1.81, 95% CI 1.52-2.15) in NMIBC patients. In patients with T1 bladder cancer (BCa), tumour multiplicity and size (≥3 cm) were also associated with worse RFS, PFS and CSS. By contrast, among patients treated with bacillus Calmette-Guérin (BCG), tumour multiplicity was not associated with worse RFS, and tumour size (≥3 cm) was not associated with worse PFS. Sessile tumours were associated with worse RFS (pooled HR 2.14, 95% CI 1.52-3.01) and PFS (pooled HR 2.17, 95% CI 1.42-3.32) compared to pedunculated tumours. Compared to papillary tumours, solid tumours were associated with worse RFS (pooled HR 1.84, 95% CI 1.25-2.72) and PFS (pooled HR 3.06, 95% CI 2.31-4.07) in NMIBC patients, and CSS in T1 BCa patients (pooled HR 2.32, 95% CI 1.63-3.30). CONCLUSIONS: Cystoscopic findings, including tumour multiplicity, size, and gross appearance, strongly predict oncological outcomes in NMIBC patients. Cystoscopic visual features can help in the decision-making process regarding the timeliness and extent of tumour resection as well as future management such as intravesical therapy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Yanagisawa T, Quhal F, Kawada T, et al. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis. BJU Int. 2023. PMID: 36479820. doi:10.1111/bju.15944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。